Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting

Richard M. BergenstalInternational Diabetes Center at Park Nicollet Minneapolis, MN, USACorrespondence[email protected]

Louis P. Garrison JrDepartment of Pharmacy, University of Washington Seattle, WA, USA

Lesley-Ann MillerEli Lilly and Company Indianapolis, IN, USA

Likun HouHealthCore, Inc. Wilmington, DE, USA

Amy BlickensderferAmylin Pharmaceuticals, Inc. San Diego, CA, USA

Anthony ZagarEli Lilly and Company Indianapolis, IN, USA

Shelley StanleyHealthCore, Inc. Wilmington, DE, USA

Anuj BhargavaIowa Diabetes and Endocrinology Center, Mercy Medical Center Des Moines, IA, USA

Rolin WadeCerner Corporation Kansas City, MO, USA

William H. HermanDepartment of Internal Medicine and Epidemiology, University of Michigan Ann Arbor, MI, USA

Your download is now in progress and you may close this window